Additional Information
Book Details
Abstract
Dr. Levy is a key leader in the field of hepatology , and she has enlisted authors who are top experts in their fields to submit state-of-the-art clinical reviews on cholestatic liver diseases. Articles are devoted to genetic determinants of cholestasis, nuclear receptors as drug targets, drug-induced cholestasis, primary sclerosing cholangitis, therapeutic advances in primary biliary cirrhosis, overlap syndromes, autoimmune sclerosing cholangitis, secondary sclerosing cholangitis, Focus is also on familial cholestasis, allagile syndrome and other hereditary causes of cholestasis, Systemic causes of cholestasis, advances in pathogenesis and treatment of pruritus, care of the cholestatic patient, and transplantation for cholestatic diseases . Readers will come away with a full overview of the diagnosis and treatment of cholestatic liver diseases.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Clinics in Liver Disease: Cholestatic Liver Diseases | i | ||
| Copyright Page | ii | ||
| Table of Contents | vii | ||
| CLINICS IN LIVER DISEASE | xi | ||
| Preface: Cholestatic Liver Diseases | xiii | ||
| Contributors | iii | ||
| Chapter 1. Genetic Determinants of Cholestasis | 147 | ||
| INTRODUCTION | 147 | ||
| INHERITED CHOLESTATIC SYNDROMES | 149 | ||
| ACQUIRED CHOLESTATIC SYNDROMES | 153 | ||
| SUMMARY | 156 | ||
| REFERENCES | 156 | ||
| Chapter 2. Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases | 161 | ||
| INTRODUCTION | 161 | ||
| NUCLEAR BA RECEPTOR FXR AND ITS BIOLOGY | 162 | ||
| FXR IN CHOLESTATIC LIVER DISEASES | 165 | ||
| THERAPEUTIC POTENTIAL OF FXR IN CHOLESTASIS | 166 | ||
| NUCLEAR XENOBIOTIC RECEPTORS PXR AND CAR AND THEIR BIOLOGY | 168 | ||
| PXR AND CAR IN CHOLESTATIC LIVER DISEASES | 169 | ||
| PXR AND CAR AS THERAPEUTIC TARGETS | 169 | ||
| VDR AND ITS BIOLOGY | 171 | ||
| VDR AND CHOLESTATIC LIVER DISEASES | 171 | ||
| VDR AS THERAPEUTIC TARGET | 172 | ||
| PPARS AND THEIR BIOLOGY | 172 | ||
| PPARS AND LIVER DISEASES | 173 | ||
| PPARS AS THERAPEUTIC TARGETS | 173 | ||
| GR AND ITS BIOLOGY | 174 | ||
| GR AS THERAPEUTIC TARGET | 175 | ||
| URSODEOXYCHOLIC ACID — CURRENT ANTI-CHOLESTATIC DRUG STANDARD AND ITS EFFECTS ON NRS | 175 | ||
| SUMMARY AND FUTURE PERSPECTIVES | 176 | ||
| REFERENCES | 176 | ||
| Chapter 3. Drug-Induced Cholestasis | 191 | ||
| INTRODUCTION | 191 | ||
| APPROACH TO THE PATIENT WITH SUSPECTED DRUG-INDUCED CHOLESTATIC LIVER INJURY | 192 | ||
| INCIDENCE OF CHOLESTATIC LIVER INJURY CAUSED BY DRUGS | 193 | ||
| RISK FACTORS | 193 | ||
| VANISHING BILE DUCT SYNDROME | 195 | ||
| THE PATHOLOGY OF DRUG-INDUCED CHOLESTASIS | 195 | ||
| THE PATHOPHYSIOLOGY OF DRUG-INDUCED CHOLESTASIS | 198 | ||
| MOST IMPORTANT DRUGS LEADING TO CHOLESTATIC LIVER INJURY | 199 | ||
| THE PROGNOSIS OF PATIENTS WITH CHOLESTASIS CAUSED BY DRUGS | 202 | ||
| REFERENCES | 203 | ||
| Chapter 4. Primary Sclerosing Cholangitis | 211 | ||
| ETIOPATHOGENESIS OF PRIMARY SCLEROSING CHOLANGITIS | 211 | ||
| EPIDEMIOLOGY AND NATURAL HISTORY | 212 | ||
| CLINICAL PRESENTATION | 213 | ||
| DIAGNOSIS | 213 | ||
| MANAGEMENT OF PATIENTS WITH PSC | 216 | ||
| FEATURES OF IBD IN PATIENTS WITH PSC | 222 | ||
| SUMMARY | 222 | ||
| REFERENCES | 222 | ||
| Chapter 5. Primary Biliary Cirrhosis: Therapeutic Advances | 229 | ||
| INTRODUCTION | 229 | ||
| MANAGEMENT | 231 | ||
| SUMMARY | 238 | ||
| REFERENCES | 238 | ||
| Chapter 6. Cholestatic Liver Disease Overlap Syndromes | 243 | ||
| CLINICAL SPECTRUM OF PBC | 244 | ||
| CLINICAL SPECTRUM OF AIH | 246 | ||
| CLINICAL SPECTRUM OF PSC | 246 | ||
| DEFINITION AND PREVALENCE OF OVERLAP SYNDROMES | 247 | ||
| DIFFERENTIAL DIAGNOSIS: IGG4 DISEASE | 248 | ||
| DIFFERENTIAL DIAGNOSIS: DRUG-INDUCED LIVER DISEASE | 249 | ||
| TREATMENT OF OVERLAP SYNDROMES | 249 | ||
| SUMMARY | 250 | ||
| REFERENCES | 251 | ||
| Chapter 7. IgG4-Associated Cholangitis | 255 | ||
| INTRODUCTION | 255 | ||
| IGG4-ASSOCIATED CHOLANGITIS | 256 | ||
| PATHOPHYSIOLOGY | 256 | ||
| CLINICAL FEATURES | 256 | ||
| DIAGNOSIS | 260 | ||
| NATURAL HISTORY | 262 | ||
| TREATMENT | 263 | ||
| SUMMARY | 265 | ||
| REFERENCES | 265 | ||
| Chapter 8. Secondary Sclerosing Cholangitis: Pathogenesis, Diagnosis, and Management | 269 | ||
| INTRODUCTION | 269 | ||
| COMMON CAUSES | 270 | ||
| CLINICAL SYMPTOMS AND DIAGNOSIS | 273 | ||
| RADIOLOGIC DIFFERENTIATION | 273 | ||
| MANAGEMENT, COMPLICATIONS, AND OUTCOMES | 274 | ||
| SUMMARY | 274 | ||
| REFERENCES | 274 | ||
| Chapter 9. Alagille Syndrome and Other Hereditary Causes of Cholestasis | 279 | ||
| INTRODUCTION | 279 | ||
| ALAGILLE SYNDROME | 279 | ||
| PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | 283 | ||
| BILE ACID SYNTHESIS DEFECTS | 285 | ||
| NIEMANN-PICK TYPE C DISEASE | 286 | ||
| CITRIN DEFICIENCY (CITRULLINEMIA TYPE II) | 288 | ||
| ARTHROGRYPOSIS-RENAL DYSFUNCTION-CHOLESTASIS SYNDROME | 289 | ||
| AAGENAES SYNDROME | 290 | ||
| NEONATAL ICHTHYOSIS-SCLEROSING CHOLANGITIS SYNDROME | 290 | ||
| ALPHA1 ANTITRYPSIN DEFICIENCY | 291 | ||
| NORTH AMERICAN INDIAN CHILDHOOD CIRRHOSIS | 292 | ||
| ZELLWEGER SYNDROME | 293 | ||
| CILIOPATHIES | 293 | ||
| SMITH-LEMLI-OPITZ SYNDROME | 294 | ||
| SUMMARY | 295 | ||
| REFERENCES | 295 | ||
| Chapter 10. Systemic Causes of Cholestasis | 301 | ||
| BACTERIAL INFECTIONS | 301 | ||
| FUNGAL HEPATITIS | 304 | ||
| MYCOBACTERIAL INFECTIONS | 305 | ||
| SYSTEMIC VIRAL INFECTIONS | 305 | ||
| HEPATIC SARCOIDOSIS | 305 | ||
| HEPATIC AMYLOIDOSIS | 306 | ||
| HEMOPHAGOCYTIC SYNDROME | 307 | ||
| SICKLE CELL DISEASE | 308 | ||
| LYMPHOMAS | 308 | ||
| SOLID ORGAN MALIGNANCIES | 309 | ||
| HEPATIC GRAFT-VERSUS-HOST DISEASE | 309 | ||
| ENDOCRINE DYSFUNCTION | 310 | ||
| CARDIAC DISEASE | 310 | ||
| SYSTEMIC AUTOIMMUNE DISEASES | 311 | ||
| TOTAL PARENTERAL NUTRITION | 311 | ||
| SUMMARY | 313 | ||
| REFERENCES | 313 | ||
| Chapter 11. Advances in Pathogenesis and Treatment of Pruritus | 319 | ||
| INTRODUCTION | 319 | ||
| STUDYING ITCH IN CHOLESTASIS | 320 | ||
| PATHOGENESIS OF PRURITUS | 321 | ||
| SUMMARY | 325 | ||
| REFERENCES | 325 | ||
| Chapter 12. Care of the Cholestatic Patient | 331 | ||
| INTRODUCTION | 331 | ||
| DIAGNOSIS | 331 | ||
| DIFFERENTIAL DIAGNOSIS | 334 | ||
| MANAGEMENT | 336 | ||
| SUMMARY | 340 | ||
| REFERENCES | 340 | ||
| Chapter 13. Liver Transplant for Cholestatic Liver Diseases | 345 | ||
| PRIMARY SCLEROSING CHOLANGITIS | 345 | ||
| PRIMARY BILIARY CIRRHOSIS | 348 | ||
| CHOLESTASIS ASSOCIATED WITH TOTAL PARENTERAL NUTRITION | 349 | ||
| BILIARY ATRESIA | 350 | ||
| ALAGILLE SYNDROME | 351 | ||
| MISCELLANEOUS CHOLESTATIC LIVER DISEASES | 352 | ||
| SUMMARY | 354 | ||
| REFERENCES | 354 | ||
| Index | 361 |